Daily FNArena News - Australia

Talent2 delivered stong growth in interim proft relative to the previous corresponding period and the market has rewarded the stock with upgrades in ratings.

Bradken fell short of market expectations with its interim result but maintained full year guidance.

Big Pharma are picking up the pace of acquisitions in the biotech sector and Southern Cross equities suggests this offers some upside to the Australian plays.

Equinox Minerals has announced a material resource upgrade at its Lumwana copper project and with scope for more to come brokers are positive on the stock.

Australian equity indices closed slightly lower in 2010, underperforming many global markets. Analysts debate whether that trend may reverse in 2011.

Starpharma is a leader in dendrimer technology and Southern Cross Equities views the stock as good value at current levels given the potential of the VivaGel product.

The outlook for Australian REITs appears solid as market conditions improve and given scope for an increase in capital management, while online is not seen as a major threat to shopping centres.

The RBA has addressed the flood situation in leaving rates unchanged but is looking at underlying trends in maintaining current policy.

The RBA today shocked no one by leaving the cash rate unchanged at 4.75%

Oil Search delivered a solid December quarter production report but upside remains tied to the development and potential expansion of the PNG LNG project.